PepGen (PEPG) Q4 2023: 29% Splicing Correction Signals Breakthrough in DM1 Therapy Development

March 6, 2024 | By EarningsIQ Research

PepGen’s clinical-stage oligonucleotide platform delivered robust single-dose splicing correction in myotonic dystrophy type 1, establishing a strong foundation for multiple upcoming trial readouts and potential disease-modifying therapies. The company’s strategic focus on Enhanced Delivery Oligonucleotide (EDO) technology underpins promising dystrophin production in Duchenne muscular dystrophy and selective RNA targeting in DM1, supported by a strengthened cash position extending runway to 2026.

Summary

• Innovative Therapeutic Validation: Single-dose PGN-EDODM1 achieved up to 29% mean splicing correction in DM1 patients, surpassing prior multi-dose clinical data.
• Robust Platform Execution: EDO51 program in DMD demonstrates potential for highest dystrophin production via exon 51 skipping, with cross-trial data supporting >9% dystrophin at higher doses.
• Clinical and Financial Momentum: Multiple pivotal data readouts anticipated in 2024 and 2025, backed by $190 million in cash post recent equity raise, enabling sustained development.

Business Overview

PepGen is a clinical-stage biotechnology company developing oligonucleotide therapies targeting severe neuromuscular and neurological diseases. The company’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides to enhance delivery of therapeutic oligonucleotides to the nucleus, aiming to correct underlying genetic pathologies. PepGen’s major clinical programs include PGN-EDO51 for Duchenne muscular dystrophy (DMD), focusing on exon 51 skipping to restore dystrophin protein, and PGN-EDODM1 for myotonic dystrophy type 1 (DM1), designed to correct RNA splicing defects.

Performance Analysis

PepGen demonstrated meaningful progress in advancing its clinical pipeline alongside solid financial management. The company reported positive initial data from the FREEDOM-DM1 Phase 1 trial, with mean splicing correction of 12.3% at 5 mg/kg and an impressive 29.1% at 10 mg/kg doses following a single administration of PGN-EDODM1. These results notably exceed splicing corrections observed in prior multi-dose DM1 trials of longer duration, signaling a potential breakthrough in disease-modifying therapy development.

On the DMD front, PepGen completed enrollment in the 5 mg/kg cohort of the CONNECT1 Phase 2 trial evaluating EDO51, with preliminary data expected mid-2024. Modeling and cross-trial comparisons suggest the potential to achieve dystrophin protein levels above 9% at the 10 mg/kg dose, which would represent an unprecedented level for exon skipping therapies. Operationally, the company is advancing multiple cohorts with regulatory clearances in the UK and plans to expand dosing geographically later in 2024.

• Cash Position Strengthened: Proceeds from an $80 million equity offering, combined with existing cash, extend PepGen's runway into 2026, supporting ongoing clinical and preclinical programs.
• R&D Expense Growth: Research and development expenses increased to $68.1 million for 2023, reflecting intensified clinical activity in DMD and DM1 programs.
• Net Loss Management: The net loss for the year was $78.6 million, consistent with investment in pipeline advancement and clinical trial execution.

The company’s financial discipline, coupled with multiple upcoming data catalysts, positions PepGen for critical inflection points in validating its EDO platform’s therapeutic potential.

Executive Commentary

Strategic Positioning

1. Differentiated EDO Platform Technology

PepGen’s EDO platform leverages cell-penetrating peptides to enhance oligonucleotide delivery to the nucleus, a critical site of action for genetic therapies. This technology underpins both PGN-EDODM1 and PGN-EDO51, enabling higher target engagement and therapeutic activity compared to conventional oligonucleotide modalities. The platform’s ability to selectively bind pathogenic RNA sequences, as in DM1, positions PepGen to address disease root causes with potentially superior efficacy and safety profiles.

2. Clinical Development Focus on Neuromuscular Diseases with High Unmet Need

By targeting DMD and DM1, PepGen focuses on rare neuromuscular diseases lacking effective disease-modifying treatments. The company’s clinical programs are designed to demonstrate functional improvements through molecular correction mechanisms—exon skipping in DMD to restore dystrophin production, and splicing correction in DM1 to alleviate myotonia and muscle weakness. These targeted approaches align with regulatory designations including orphan and fast track status, facilitating accelerated development pathways.

3. Data-Driven Dose Escalation and Regulatory Engagement

PepGen employs a stepwise dose escalation strategy in its clinical trials, with data safety monitoring boards reviewing emerging safety profiles before advancing doses. Recent regulatory clearances in the UK and ongoing dialogues with FDA reflect active engagement to align trial designs with approval requirements. The company’s planned data readouts in 2024 and 2025 are critical milestones to validate dosing, efficacy, and safety, supporting potential accelerated approvals.

4. Financial Position Enabling Sustained R&D Investment

The successful $80 million equity raise in early 2024, combined with existing cash reserves, extends PepGen’s cash runway into 2026. This financial flexibility supports continued advancement of multiple clinical and preclinical programs, manufacturing scale-up, and regulatory activities without near-term capital constraints, critical for a clinical-stage biotech with multiple ongoing trials.

5. Pipeline Expansion and Preclinical Progress

Beyond lead programs, PepGen is advancing PGN-EDO53 targeting exon 53 skipping in DMD, representing approximately 8% of the patient population. IND and CTA enabling studies are underway, indicating a strategic pipeline expansion to broaden therapeutic reach within the DMD community and further leverage the EDO platform’s capabilities.

Key Considerations

PepGen’s Q4 2023 results illustrate a clinical and financial inflection point driven by the EDO platform’s promising early data. Investors should weigh the following considerations as the company progresses:

• Clinical Validation of Splicing Correction: The 29.1% mean splicing correction at 10 mg/kg single dose in DM1 patients is a significant milestone, yet functional benefits require confirmation in multiple-dose studies.
• Dystrophin Production as a Surrogate Endpoint: The potential to exceed 9% dystrophin production with EDO51 could redefine therapeutic benchmarks for exon skipping therapies, but clinical correlation with functional outcomes remains critical.
• Regulatory Pathway Complexity: Navigating approvals for rare genetic diseases involves evolving endpoints and regulatory expectations, particularly for DM1 where primary endpoints are still under discussion.
• Operational Execution Risk: Timely patient recruitment, trial site activation, and data reporting are essential to maintain momentum and investor confidence.
• Financial Sustainability: While cash runway extends to 2026, ongoing investment needs for clinical trials and pipeline expansion require prudent capital allocation and potential future funding considerations.

Risks

PepGen faces typical clinical-stage biotech risks, including the uncertainty of translating molecular correction into meaningful clinical benefit, potential adverse safety findings in escalating dose cohorts, and regulatory delays or non-approvals. Additionally, the competitive landscape for DMD and DM1 therapies and evolving regulatory standards could impact development timelines and market positioning. Operational challenges in trial execution and patient enrollment may also affect milestone delivery.

Forward Outlook

For 2024, PepGen anticipates:

• Preliminary data reporting from the CONNECT1 5 mg/kg cohort in mid-2024, covering safety, exon skipping, and dystrophin production.
• Initial clinical data from the FREEDOM-DM1 Phase 1 trial’s 5 mg/kg cohort in the second half of 2024, including safety, splicing correction, and functional assessments.

For 2025, the company expects to:

• Report data from the 10 mg/kg cohort of CONNECT1 and potentially initiate higher dose cohorts.
• Advance FREEDOM2 multiple ascending dose trial for DM1, with initial results anticipated in early 2026.
• Progress regulatory submissions and trial initiations for CONNECT2 in multiple geographies.

Management emphasizes ongoing regulatory engagement and data-driven dose escalation as key to optimizing clinical development and positioning for potential accelerated approval pathways.

Takeaways

PepGen’s Q4 2023 disclosures reveal a company advancing from early-stage development into pivotal clinical validation, supported by a differentiated delivery platform and focused on rare neuromuscular diseases with high unmet need. The robust splicing correction in DM1 and promising dystrophin production projections in DMD underscore the platform’s potential to deliver transformative therapies.

• Clinical Differentiation: The magnitude of splicing correction from a single dose in DM1 sets PepGen apart from competitors and supports the rationale for multiple ascending dose studies to assess functional benefit.
• Strategic Execution: The stepwise clinical development approach, coupled with regulatory designations and financial strength, provides a clear pathway to milestone-driven value creation.
• Investor Focus: Upcoming mid-2024 and late-2024 data releases will be critical inflection points to validate therapeutic hypotheses and inform longer-term commercial potential.

Conclusion

PepGen’s Q4 2023 results mark a significant advancement in its mission to develop oligonucleotide therapies for neuromuscular diseases. The company’s EDO platform has demonstrated compelling early clinical activity, supported by a robust financial position and a clear development roadmap. Investors should monitor forthcoming clinical data and regulatory progress as key indicators of PepGen’s potential to deliver disease-modifying treatments in DMD and DM1.

Industry Read-Through

PepGen’s demonstration of high-level splicing correction and promising dystrophin production reinforces the evolving potential of oligonucleotide therapies in rare genetic neuromuscular diseases. The company’s success in leveraging cell-penetrating peptides to enhance nuclear delivery may influence platform strategies across the sector. Additionally, PepGen’s approach to dose escalation and regulatory engagement offers a model for balancing innovation with clinical and safety rigor. These developments warrant close attention from investors and competitors in the RNA therapeutics and rare disease biotech landscape.

PEPG Healthcare Biotechnology Neuromuscular Oligonucleotide Exon Skipping Splicing Correction Rare Disease